Hypertension is one of the major risk factors in the DM patients. When both the disorders are present in the patient, then there is a very high risk of CVS, cerebrovascular and renal events. The role of various antihypertensive agents in such a patients was evaluated by the meta-analysis of various studies. A recent publication in the BMJ revealed through the analysis of various studies that RAS blockers are not better than the other antihypertensive agents to avoid the hard outcomes of the diseases.
DM patients are always at high risk of CVS and renal events. The previously reported study results have shown the significant benefit of RAS in the CVS and renal events. Various guidelines have also recommended RAS in diabetes and hypertension. But in contrast, few other guidelines have mentioned that any class antihypertensive agents can be used in people with diabetes and recommended RAS…
